Company intelligence / Profile preview

SunVax mRNA Therapeutics

Beverly, Massachusetts, United Statessunvaxmrna.com ↗

Ownership: Private
Development stage: Preclinical

Overview

SunVax has developed LNP-samRNA therapy showing remarkable efficacy in animal models with tumor-free rates of up to 80% in B16F10 models. Their RSV vaccine has demonstrated comparable performance to Moderna's and GSK's RSV vaccines.

Therapeutic areas: OncologyRare DiseasesImmunologyInfectious Diseases
Modalities: mRNA therapeuticsself-amplifying mRNA (samRNA)lipid nanoparticle (LNP) delivery technology
Industry: Biotech

Drug pipeline

5 assets

SV-IO-002

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Development partners mentioned but not specifically named

Beyond the preview

Go deeper on SunVax mRNA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SunVax mRNA Therapeutics.

Explore the full profile